

## Leading UK Digital Care Planning Software Provider Nourish Care Establishes Channel Partnership with PainChek

PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smart based pain assessment and monitoring application, is pleased to announced it has established a reseller agreement with [Nourish Care](#), a leading UK care management software provider.

The agreement has an initial 12-month term with an opportunity to renew by both parties and will facilitate sales of the PainChek® digital pain assessment app directly through Nourish, which currently supports more than 320,000 people receiving care<sup>1</sup> across multiple care settings, including residential, disability and home care. PainChek® is already contracted to be licensed for use across ~25,000 beds in 600 UK aged care facilities<sup>2</sup>, where there are currently 900,000 people living with dementia, projected to rise to 1.6 million by 2040<sup>3</sup>.

The PainChek® and Nourish integration, which was launched in 2022, facilitates best-practice pain management in real-time, including monitoring and improving assessment practices and pain outcomes by resident, facility, and across the group via PainChek® Analytics.

PainChek® assessments, which combine intelligently automated, AI-driven pain scores and a Numerical Rating Scale (NRS), are sent to Nourish instantly upon completion at the point of care. Consistent, best-practice pain management has been shown to lead to significant benefits, such as a 40% decrease in distress, a 20% reduction in falls, and a 40% drop in medication-related incidents<sup>4</sup>.

Commenting on the new agreement between PainChek and Nourish Care, PainChek CEO and Managing Director Philip Daffas said:

*“Since 2022, the best-in-class integration between PainChek® and Nourish Care has facilitated best-practice pain management and quality, technology-driven care. This latest agreement strengthens our existing partnership and is set to rapidly accelerate PainChek®’s sales in the UK by leveraging Nourish’s current client base across home care, disability and the 500,000 aged care bed market.”<sup>5</sup>*

Nourish Care Director of Partner and Business Engagement Denise Tack, commented:

*“We are delighted to grow our partnership with PainChek, to help an increasing number of care providers across the UK. Our integration with PainChek® has been highly successful, without barriers to implementation. As we go to clients, we have the ability to activate*

*PainChek® immediately with the touch of a button. It means that all our clients, whether new or existing, can easily benefit from better, resident-focused care, which is great for all involved."*

The Company is unable to provide an estimate for the revenue to be derived from this agreement, however sales will be included in PainChek's future consolidated financial reports.

For more information, visit: [www.painchek.com](http://www.painchek.com).

#### References:

- 1- Nourish Care Website - <https://nourishcare.com/who-we-help/>
- 2 & 5- PainChek Quarterly update ASX release 30<sup>th</sup> January 2024 <https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02766534-2A1501667>
- 3 – Local Dementia Statistics. Alzheimer's Society (2024). <https://www.alzheimers.org.uk/about-us/policy-and-influencing/local-dementia-statistics>
- 4- Cheryl Baird, Hannah Miller, Kreshnik Hoti, and Jeffery Hughes. Clinical impact of a multifaceted intervention aimed at decreasing distress in people living with dementia: evaluating the Reconnect program. *Frontiers in Psychiatry* (2023) <https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsy.2023.1191105/full>

*The announcement has been approved for release by the Board of Directors.*

For more information:

Natalie Climo

Company Secretary, PainChek

[natalie.climo@boardroomlimited.com.au](mailto:natalie.climo@boardroomlimited.com.au)

02 8016 2875

Philip Daffas

CEO, PainChek

[philip.daffas@painchek.com](mailto:philip.daffas@painchek.com)

0406 537 235

#### About PainChek

[PainChek®](#) is the world's first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek® app is available on smartphones and tablets and combines PainChek's AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek's detailed reporting suite, PainChek® Analytics.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom, with FDA review in the United States currently in progress.

PainChek® has contracts with over 1,000 aged care facilities, with more than 4,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek®, facilities can:

- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias
- Streamline the pain assessment process for time-poor carers, with access to the PainChek® tool, the NRS, pain trends, and charting in one solution
- Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
- Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centres have been published in various peer-reviewed journals including the [Journal of Alzheimer's Disease](#). An article in [BMC Geriatrics](#) indicates that PainChek® is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found [here](#).

PainChek® has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated [PainChek® Infant app](#) identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: <https://painchek.com>